CN1872329A - Application of medication composition of containing giant gen-seng in preparing medicine for treating insufficiency of blood supply for brain - Google Patents

Application of medication composition of containing giant gen-seng in preparing medicine for treating insufficiency of blood supply for brain Download PDF

Info

Publication number
CN1872329A
CN1872329A CNA200510013684XA CN200510013684A CN1872329A CN 1872329 A CN1872329 A CN 1872329A CN A200510013684X A CNA200510013684X A CN A200510013684XA CN 200510013684 A CN200510013684 A CN 200510013684A CN 1872329 A CN1872329 A CN 1872329A
Authority
CN
China
Prior art keywords
parts
radix
rhizoma
semen
fructus
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CNA200510013684XA
Other languages
Chinese (zh)
Inventor
范立君
李永强
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Tianjin Tasly Pharmaceutical Co Ltd
Original Assignee
Tianjin Tasly Pharmaceutical Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Tianjin Tasly Pharmaceutical Co Ltd filed Critical Tianjin Tasly Pharmaceutical Co Ltd
Priority to CNA200510013684XA priority Critical patent/CN1872329A/en
Publication of CN1872329A publication Critical patent/CN1872329A/en
Pending legal-status Critical Current

Links

Abstract

An application of the medicinal composition composed of ginseng, astragalus root, Chinese angelica root and pilose antler in preparing the medicines for treating chronic cerebral ischemia is disclosed.

Description

A kind of Radix Ginseng pharmaceutical composition that contains is preparing the application for the treatment of in the chronic insufficient cerebral blood supply medicine
Technical field
The invention belongs to field of medicaments, be specifically related to a kind of application of Radix Ginseng pharmaceutical composition in preparation treatment chronic insufficient cerebral blood supply medicine that contain.
Background technology
The origin of notion
Chronic insufficient cerebral blood supply (Chronic Cerebral Circulation Inefficiency, CCCI) blood supply that refers to the brain integral level reduces the state of (being lower than 40-60ml/100g cerebral tissue/per minute), but not focal cerebrum ischemia.It is the new name of disease of year proposition surplus in the of external preceding 10.The old age or the presenium patient that often have some to tell subjective symptomss such as nose heave, dizziness repeatedly clinically, except ocular fundus arteriosclerosis, both also not have cranium brain CT unusual for the focal sign of impassivity infringement, and these patients often are diagnosed as " cerebral arteriosclerosis ".As everyone knows, there are difference in the notion of cerebral arteriosclerosis and clinical diagnosis standard long-term.The chaos of conception that the so-called cerebral arteriosclerosis name of disease of always using for fear of people causes, Japanese health ministry has entrusted " about the definition and the diagnostic criteria tutorial class of cerebral arteriosclerosis disease " to study, cerebral arteriosclerosis has been made the corrigendum motion, think that previously cerebral arteriosclerosis, broad sense system include pathological notion of all diseases related that cerebral arteriosclerosis such as lacuna infarction causes; Narrow sense then refers to because cerebral arteriosclerosis causes the conscious slight neural mental symptom that is produced under the pathological state of disturbance of cerebral circulation, the focal sign of impassivity system and to stare at imaging examination unusual.The 16th apoplexy association of Japan formally was referred to as it chronic cerebral circulatory failure (Chronic Cerebral Circulation Inefficiency), i.e. CCCI in 1991.
International research shows that the harm of chronic insufficient cerebral blood supply is a lot.Specifically be summarized as follows:
● the atrophy of cortex atrophy----cortex is the basic pathological change that causes senile dementia
● the neurogenous degeneration of Hippocampus
● frontal lobe, Hippocampus M type cholinoceptor combination rate decline alba are loosened--and-Yi causes occurring hypomnesis, retrograde amnesia occurs
● glial cells hyperplasia---cause brain function to descend
● capillary bed changes
● other neural subjective symptoms obstacle
The diagnosis of CCCI
For CCCI is studied all sidedly, Japan scholar horizontal well is divided into 3 groups with the age the old man more than 60 years old, the A group is: subjective symptoms outbreaks such as dizziness, carebaria are arranged, more than the ocular fundus arteriosclerosis KWII, but do not have also Non Apparent Abnormality person of any focal neurosigns, CT scan; The B group is: except that subjective symptomss such as no dizziness, other conditions are identical with the A group: the C group is cotemporary healthy old men. and these three groups are all carried out CT, MRI, TCD and PET and check. and check result is: (1) TCD measures common carotid artery blood flow and shows that the .A group all significantly lowers for two groups than B, C; (2) PET shows Interhemispheric blood flow, and the A group significantly lowers than the C group; (3) MRI finds to have in the A group 55%, has 15% old man to find to have cerebral infarction or lacuna infarction in B and the C group.Its conclusion is: cerebral blood flow lowers near normal 80%, subjective symptomss such as dizziness just may occur; The appearance of mental symptom and nervous symptoms then must be lower than below 80% by blood flow.It should be noted that. the patients' of these dizzy outbreaks TCD and PET to be checked find. the blood flow in carotid artery system and cerebral hemisphere perfusion district thereof and the blood flow of vertebra basilar artery lower equally, therefore clinically dizzy symptom is belonged to vertebro-basilar artery insufficiency without exception seem comprehensive inadequately.Japanese health ministry blood circulation diseases tutorial class (1990) is studied the diagnostic criteria of having worked out CCCI in view of the above, sees the following form 1.
Table 1 chronic insufficient cerebral blood supply (CCCI) diagnostic criteria (one)
Since subjective symptoms undulatory property growth and decline such as that the circulatory disturbance of brain causes is nose heave, dizziness, but diagnostic imaging aspects such as clinical manifestation and CT all find no the finding of pointing out the vascular encephalosis, and do not belong to TIA category person.
1. clinical manifestation
(1) because various subjective symptomss (carebaria, dizziness etc.) the undulatory property growth and decline that the circulatory disturbance of brain causes.
(2) the focal sign of brain does not appear.
(3) most accompanied with hypertension.
(4) the optical fundus tremulous pulse is arteriosclerosis and sexually revises.
(5) can hear vascular murmur at the perfusion tremulous pulse.
2.CT finding " does not see that the vascular encephalosis becomes ".
Other
(1) cerebral angiography or cervical region TCD etc. show brain perfusion arterial occlusion or narrow change.
(2) cerebral circulation is measured and is shown that blood flow lowers.
(3) age is basically more than 60.
(4) got rid of other disease that can cause above-mentioned subjective symptoms definitely.
(1996) such as nearly rattans make further research 60 routine CCCI patients with said method, except that obtaining above-mentioned similar result of study, still observing CCCI patient further descends with the age growth common carotid artery blood flow, the all sites cerebral blood flow of each cerebral lobe and brain oxidative metabolism rate all descend obviously, think because atherosclerosis risk factors such as hypertension have caused the sclerosis of the mobile arteries and veins of brains.Cause diffuse cerebral blood flow and brain poor metabolism to produce the subjective symptoms of CCCI.Performance is not focal in view of the CCCI cerebral lesion, thus do not occupy transient ischemic attack (transient ischemic attack) category, and drawn more practical CCCI diagnostic criteria (seeing the following form 2).
Table 2 chronic insufficient cerebral blood supply (CCCI) diagnostic criteria (two)
1. subjective symptomss such as nose heave, dizzy, different fiber crops are arranged
2. the finding of supporting cerebral arteriosclerosis is arranged.
(1) with hypertension, ocular fundus arteriosclerosis change etc.
(2) vascular murmur of audible and brain perfusion tremulous pulse sometimes.
3. do not see the focal neurosigns of brain.
4. type CT or MRI check that affirmation does not have the cerebral lesion of the device matter of vascular.
5. get rid of because the above-mentioned subjective symptoms that other disease causes.
6. the age is in principle greater than 60 years old.
7. the cerebral circulation inspection confirms that cerebral blood flow is low.
8. definite brain perfusion tremulous pulse such as cerebral angiography, cervical region TCD has obturation, narrow sick.
Be born in 2000 the up-to-date diagnostic criteria of CCCI, its particular content is as follows:
" CCCI diagnostic criteria " version in 2000
1. subjective symptomss such as dizziness, headache, head sink;
2. the finding of supporting cerebral arteriosclerosis is arranged: (1) is with hypertension, ocular fundus arteriosclerosis change etc.; Or the vascular murmur of (2) audible and brain perfusion sometimes tremulous pulse;
3. the focal neurosigns that does not have brain;
4.CT having the organic brain of vascular, MRI do not change;
5. get rid of the above-mentioned subjective symptoms that other diseases causes;
6. the age is in principle greater than 60 years old (can be loosened to more than 45 years old);
7. cerebral circulation confirms that cerebral blood flow is low;
8.DSA or TCD prompting brain perfusion tremulous pulse has inaccessible or narrow change.
Compare with early stage version diagnostic criterias in 96 years, this edition standard is opinion, clear and definite more.Its typing sees the following form 3.
The international typing of table 3 chronic insufficient cerebral blood supply
I type: simple chronic insufficient cerebral blood supply
II type: the change of CCCI+ brain essence (MRI CT find the lacuna infarction)
Over past ten years, domestic many scholars compare comprehensive clinical research to CCCI, the blood properties such as blood viscosity fluid rheology index of observing most of CCCI patients reaches Fibrinogen unusually and obviously raises, and thinks that these also have bigger influence to the formation of CCCI or the fluctuation of symptom unusually; CT sees at the end unusual many patients. cranium brain MRI often can detect ischemic focus (the T1 weighted signal is no abnormal, T2 weighting and proton become to protect the slightly high signal of visible stigma point-like); Adopt the TCD dynamic measurement except that common carotid artery, main vascular flow lowers in the brain of still visible many places, for the clinical diagnosis of CCCI has increased new content.
The treatment of CCCI
According to table 1 and table 3, all dizzinesses that the undulatory property growth and decline are arranged, subjective symptoms such as nose heave, CT, MRI do not see vascular brain organic focus person, should belong to simple property CCCI, be considered to the cerebral infarction state of generation last stage, be necessary to carry out positive control, need improve the risk factor (as hypertension, diabetes, hyperlipemia, obesity etc.) of cerebral circulation and removal ischemic cerebrovascular (ICW), preferably adjoin anti-platelet aggregation medicines such as pyridine with aspirin, thiophene chlorine simultaneously, several days clinical subjective symptomss.And TCD or PET measure brain trunk tremulous pulse are arranged (vertebra-basilar artery system or/carotid artery system) blood flow reduction person, belong to compensatory phase CCCI, should take corresponding prevention and health care measure at the ICVD risk factor that exists, symptoms such as clinical appearance dizziness, CT shows ischemic brain material change (cerebral infarction, lacuna infarction), and TCD or PET confirm to have cerebral blood flow attenuating person.Then belong to CCCI II type or III type, should press lacuna infarction or cerebral infarction respectively and handle.
At present, the medicine for the treatment of the CCCI use clinically has: THA: cholinesterase inhibitor, GST-21: maincenter type N cholinoceptor inhibitor, FK506: immunosuppressant, Nimsuperzine:Cox-2 inhibitor etc., all obtained recent preferably clinical efficacy, late result remains further to be studied.Traditional Chinese medicine of China is having unique effect aspect the treatment CCCI.
Through research for many years, the inventor finds that the compositions be made up of Radix Ginseng, the Radix Astragali etc. has the treatment chronic insufficient cerebral blood supply, and by the effect of other brain diseasess of its initiation.
Summary of the invention
The object of the invention is to provide the new purposes of aforementioned pharmaceutical compositions aspect the treatment chronic insufficient cerebral blood supply.
The prescription of this pharmaceutical composition is formed as follows by weight ratio:
9~11 parts of Radix Ginsengs, the Radix Astragali 39~41,14~16 parts of Radix Angelicae Sinensis, 9~11 parts in Cornu Cervi Pantotrichum, 79~81 parts of Flos Chrysanthemis, 79~81 parts of Herba Menthaes, 79~81 parts of Radix Bupleuri, 79~81 parts of Semen Cassiaes, Herba Schizonepetae 39~41,79~81 parts of Radix Salviae Miltiorrhizaes, 99~101 parts of Radix Polygalaes, 24~26 parts of Fructus Schisandrae Chinensis, 39~41 parts of Semen Ziziphi Spinosaes, 39~41 parts of Plumula Nelumbiniss, 59~61 parts of Radix Ophiopogonis, 59~61 parts of Bulbus Liliies, 19~21 parts of Caulis Bambusae In Taenia, 79~81 parts of Radix Scutellariaes, 79~81 parts of Radix Platycodoniss, 19~21 parts of Pericarpium Citri Reticulataes, 39~41 parts in Poria, 19~21 parts in Radix Glycyrrhizae, 2~3 parts of Rhizoma Zingiberiss, 79~81 parts of Radix Et Rhizoma Rhei, 39~41 parts of Semen Platycladi, 79~81 parts of Rhizoma Acori Graminei, 59~61 parts in Semen Persicae, 19~21 parts of Radix Achyranthis Bidentataes, 14~16 parts of Fructus Viticises, 79~81 parts of Rhizoma Et Radix Notopterygiis, 79~81 parts of Ramulus Uncariae Cum Uncis, 39~41 parts of Radix Puerariaes, 39~41 parts of the Radixs Angelicae Dahuricae, 59~61 parts on Flos Carthami, 59~61 parts of Rhizoma Chuanxiongs, 19~21 parts of Semen Nelumbinis, 9~11 parts of Caulis Akebiaes, 39~41 parts in Gypsum Fibrosum, 19~21 parts of the Rhizoma Pinelliaes, 19~21 parts of Fructus Aurantiis, 1~3 part of Borneolum Syntheticum, 39~41 parts of Cortex Phellodendris, 19~21 parts of the Rhizoma Anemarrhenaes, 59~61 parts of Radix Paeoniae Rubra, 79~81 parts of Fructus Crataegis, 79~81 parts of Rhizoma Ligusticis, 19~21 parts of Radix Saposhnikoviaes, 19~21 parts of Radix Rehmanniae;
Best proportioning is:
10 parts of Radix Ginsengs, 40 parts of the Radixs Astragali, 15 parts of Radix Angelicae Sinensis, 10 parts in Cornu Cervi Pantotrichum, 80 parts of Flos Chrysanthemis, 80 parts of Herba Menthaes, 80 parts of Radix Bupleuri, 80 parts of Semen Cassiaes, Herba Schizonepetae 40,80 parts of Radix Salviae Miltiorrhizaes, 100 parts of Radix Polygalaes, 25 parts of Fructus Schisandrae Chinensis, 40 parts of Semen Ziziphi Spinosaes, 40 parts of Plumula Nelumbiniss, 60 parts of Radix Ophiopogonis, 60 parts of Bulbus Liliies, 20 parts of Caulis Bambusae In Taenia, 80 parts of Radix Scutellariaes, 80 parts of Radix Platycodoniss, 20 parts of Pericarpium Citri Reticulataes, 40 parts in Poria, 20 parts in Radix Glycyrrhizae, 2.5 parts of Rhizoma Zingiberiss, 80 parts of Radix Et Rhizoma Rhei, 40 parts of Semen Platycladi, 80 parts of Rhizoma Acori Graminei, 60 parts in Semen Persicae, 20 parts of Radix Achyranthis Bidentataes, 15 parts of Fructus Viticises, 80 parts of Rhizoma Et Radix Notopterygiis, 80 parts of Ramulus Uncariae Cum Uncis, 40 parts of Radix Puerariaes, 40 parts of the Radixs Angelicae Dahuricae, 60 parts on Flos Carthami, 60 parts of Rhizoma Chuanxiongs, 20 parts of Semen Nelumbinis, 10 parts of Caulis Akebiaes, 40 parts in Gypsum Fibrosum, 20 parts of the Rhizoma Pinelliaes, 20 parts of Fructus Aurantiis, 2.5 parts of Borneolum Syntheticums, 40 parts of Cortex Phellodendris, 20 parts of the Rhizoma Anemarrhenaes, 60 parts of Radix Paeoniae Rubra, 80 parts of Fructus Crataegis, 80 parts of Rhizoma Ligusticis, 20 parts of Radix Saposhnikoviaes, 20 parts of Radix Rehmanniae.
This patent drug compositions is implemented by following scheme:
The material of getting it filled according to the above ratio, extracting in water 3 times, each 1 hour, merge extractive liquid,, suitably concentrate, add the ethanol of 2 times of amounts, leave standstill 24 hours precipitations, get supernatant concentration and become extractum, relative density is 1.3~1.4, and paste-forming rate is 10%, and qinghuo reagent is spray dried to powder.Wherein, preparation part can also be made any dosage form on other pharmaceuticss according to the process of routine.
Chronic insufficient cerebral blood supply (CCCI) has close getting in touch with brain symptoms such as dizziness, headaches, but at aspects such as pathogenesis and Therapeutic Method tangible difference is arranged again.At present, for chronic insufficient cerebral blood supply, also mainly be based on the pharmaceutical intervention treatment, there is not clear and definite medicine.The medicine of treatment headache not necessarily has the effect of treatment chronic insufficient cerebral blood supply, even also can cause other untoward reaction.
In order to understand the present invention better, treatment chronic insufficient cerebral blood supply rat model is dizzy, the influence of learning and memory below by the oral liquid formulation of observing aforementioned pharmaceutical compositions (being called for short " oral liquid " down), and the therapeutical effect of this pharmaceutical composition aspect the treatment chronic insufficient cerebral blood supply is described.
Experimental example: oral liquid treatment chronic insufficient cerebral blood supply experimentation of the present invention
One, materials and methods
1. animal grouping: 100 of male SD rats, in 10 ages in week, body weight 250 ± 20g is divided into 3 groups at random: oral liquid group, nimodipine group, model control group, every group each 20.Oral liquid group 8 weeks after modeling begin to gavage Chinese medicine oral liquid 2g/kg/ days, once a day, and continuous 4 weeks; The nimodipine group substitutes oral liquid with equal-volume nimodipine (500ug/kg), and is surplus with the oral liquid group; Model control group substitutes oral liquid with the equal-volume normal saline, and is surplus with the oral liquid group.
Medicine: nimodipine, nimodipine tablet, Shanxi Yabao Pharmaceutical Co., Ltd. produces, and lot number is that the accurate word (196) of medicine is defended No. 048095 in the Shanxi, every day 3 times, each 20mg, oral; Oral liquid, Tianjin Tasly Pharmaceutical Co., Ltd.
2. rat chronic cerebral blood supply insufficiency model development: with reference to Torre[Torre Jc, Fortin t, park GA, et al.ChroniccereBRovascular insufficiency induces dementia-induces dementia-like deficits in agedrats.Brain Res, 1992,582 (2): 186-195.] etc. method is made rat both sides ligation of carotid models (2VO).Rat is got the cervical region median incision and cuts off skin through being fixed in behind the 10% chloral hydrate 3.0ml/kg intraperitoneal injection of anesthesia on the operation plate, and passivity is separated each layer tissue, see in the neck that the external carotid artery bifurcated separates vagus nerve, prick bilateral common carotid arteries, layer-by-layer suture with the 4-0 toe-in.Keep 37 ℃-38 ℃ of anus temperature, 23 ℃ of postoperative feeding environment temperature, free diet in the art.
3. learning and memory is measured: adopt Y type maze experiment.Rat is placed in the Y type labyrinth box, began experiment after conforming 3 minutes.The rat of shocking by electricity successively clockwise, the learning and memory in rats achievement has 9 correct required number of shocks to represent to reach in continuous 10 times, how much represent the quality of learning and memory function with reaching 9/10 correct required number of shocks.Laboratory animal respectively at 2VO before, respectively carry out Y type labyrinth test and record achievement behind the 2VO behind 8 weeks, the 2VO behind 12 weeks, the 2VO 16 weeks.
4. measure dizzy incubation period: regulate rotation inducing instrument rotary speed 200r/min.The rat rotation was placed in charged insulating 50 * 50 * 40 experimental boxs on every side in bottom in 1 minute, at once electric shock.(cylindrical rubber of the high 10cm of a diameter 6.5cm is put by experimental box central authorities).Rat stops to jumping onto rubber column escape electric shock and keeping being dizzy incubation period in 30 seconds at rubber column from rotation.Incubation period, long prompt was dizzy serious more more.Each measured once dizzy incubation period to all animals 16 weeks behind 12 weeks, the 2VO behind 8 weeks, the 2VO before 2VO, behind the 2VO.
Two, experimental result
1. oral liquid is to the influence of chronic insufficient cerebral blood supply learning and memory function: Y shape maze test learning and memory in rats achievement has 9 correct required number of shocks to represent to reach before all rat modelings in continuous 10 times, how much represents the quality of learning and memory function with reaching 9/10 correct required number of shocks.As shown in table 1, correct learning and memory function approximately needs about 18-20 time before the rat 2VO.Behind the rat 2VO, along with time lengthening, the learning and memory achievement descends gradually.The correct learning and memory achievement of 2VO12 week rat is electric shock about 39.5 times, and 16 weeks were about 58.3 times; Nimodipine group and 2VO group no significant difference, P>0.05.12 weeks of oral liquid group, the correct learning and memory achievement with 16 weeks was that shock count is respectively 29.2 and 43.2 times, and organizing with 2VO relatively has notable difference, P<0.05.The prompting oral liquid can effectively improve the 2VO learning and memory function.
Table 1 oral liquid is to the influence of chronic insufficient cerebral blood supply learning and memory function
Group n Learning and memory achievement (X ± SD time)
Before the 2VO 8 weeks behind the 2VO 12 weeks behind the 2VO 16 weeks behind the 2VO
2VO group nimodipine group oral liquid group 15 15 15 8.6±2.1 8.9±1.8 9.1±2.3 17.3±2.3 16.2±1.9 15.2±2.0 39.5±4.3 35.3±4.5 29.2±3.9* 58.3±8.5 51.2±7.3 43.2±6.2*
* compare P<0.05 with the 2VO group
2. the oral liquid influence dizzy to the chronic insufficient cerebral blood supply rat: as shown in table 2, be about 96 seconds dizzy incubation period before all rat modelings.Behind the rat 2VO, along with time lengthening increases dizzy incubation period.As shown in table 1, be respectively 17.3 ± 2.3,39.5 ± 4.3,58.3 ± 8.5 the dizzy incubation period that 2VO organizes 8 weeks, 12 weeks, 16 weeks, and notable difference arranged, P>0.05 before the 2VO.Nimodipine treatment each time point of back and 2VO group no significant difference, P>0.05.Be respectively correct 112.12 ± 16,127.41 ± 26,134.14 ± 31 the dizzy incubation periods in oral liquid group 12 week and 16 weeks, notable difference, P<0.05 relatively arranged with the 2VO group.The prompting oral liquid can effectively improve dizzy effect incubation period of 2VO rat.
Table 2 oral liquid is to the dizzy preclinical influence of chronic insufficient cerebral blood supply rat
Group n Dizzy incubation period (X ± SD second)
Before the 2VO 8 weeks behind the 2VO 12 weeks behind the 2VO 16 weeks behind the 2VO
Sham operated rats 2VO group nimodipine group oral liquid group 1 15 15 15 5 96.24±12 95.12±14 96.21±22 97.25±18 95.21±19 130.34±24# 128.23±26 112.12±16* 96.24±12 147.32+34# 143.13±36 127.41±26* 95.21±19 153.13±52# 148.52±42 134.14±31*
# and sham operated rats be P<0.05 relatively; * compare P<0.05 with the 2VO group
Three, discuss
1992, Torre etc. reported that at first ligation rat bilateral carotid causes the chronic insufficient cerebral blood supply model to succeed.Subsequently studies confirm that 2VO rat hippocampus CA1 district neural degeneration, cortex atrophy, white matter are loose, microglia hypertrophy and capillary bed change etc.The 2VO rat promptly enters chronic phase after 3 weeks, and frontal lobe appears to the 2VO3 rat in rat after 3 months, Hippocampus M type cholinoceptor combination rate descends, and monoamine class mediator changes and the energy metabolism compensatory activates and neuroethology changes.
This experimentation confirms that aspect learning and memory mensuration the correct learning and memory achievement in 12 weeks of oral liquid group and 16 weeks is that shock count is respectively 29.2 and 43.2 times, with the 2VO group notable difference, P<0.05 is arranged relatively.The prompting oral liquid can effectively improve the 2VO learning and memory function; In dizzy incubation period of influence experiment, be respectively correct 112.12 ± 16,127.41 ± 26,134.14 ± 31 the dizzy incubation periods in 12 weeks of oral liquid group and 16 weeks, with the 2VO group notable difference, P<0.05 are arranged relatively.The prompting oral liquid can effectively improve dizzy effect incubation period of 2VO rat.
In sum, this experimental result shows that this pharmaceutical composition has the chronic insufficient cerebral blood supply of improvement rat blood circulation, improves effects such as the dizziness that causes because of chronic cerebral ischemia and dysmnesia.
The specific embodiment
The present invention is further illustrated below in conjunction with embodiment, and following this embodiment only is used to the present invention is described and to the present invention without limits.
Embodiment 1
By the following weight material of getting it filled:
Radix Ginseng 10g, Radix Astragali 40g, Radix Angelicae Sinensis 15g, Cornu Cervi Pantotrichum 10g, Flos Chrysanthemi 80g, Herba Menthae 80g, Radix Bupleuri 80g, Semen Cassiae 80g, Herba Schizonepetae 40g, Radix Salviae Miltiorrhizae 80g, Radix Polygalae 100g, Fructus Schisandrae Chinensis 25g, Semen Ziziphi Spinosae 40g, Plumula Nelumbinis 40g, Radix Ophiopogonis 60g, Bulbus Lilii 60g, Caulis Bambusae In Taenia 20g, Radix Scutellariae 80g, Radix Platycodonis 80g, Pericarpium Citri Reticulatae 20g, Poria 40g, Radix Glycyrrhizae 20g, Rhizoma Zingiberis 2.5g, Radix Et Rhizoma Rhei 80g, Semen Platycladi 40g, Rhizoma Acori Graminei 80g, Semen Persicae 60g, Radix Achyranthis Bidentatae 20g, Fructus Viticis 15g, Rhizoma Et Radix Notopterygii 80g, Ramulus Uncariae Cum Uncis 80g, Radix Puerariae 40g, Radix Angelicae Dahuricae 40g, Flos Carthami 60g, Rhizoma Chuanxiong 60g, Semen Nelumbinis 20g, Caulis Akebiae 10g, Gypsum Fibrosum 40g, Rhizoma Pinelliae 20g, Fructus Aurantii 20g, Borneolum Syntheticum 2g, Cortex Phellodendri 40g, Rhizoma Anemarrhenae 20g, Radix Paeoniae Rubra 60g, Fructus Crataegi 80g, Rhizoma Ligustici 80g, Radix Saposhnikoviae 20g, Radix Rehmanniae 20g;
Above-mentioned medical material extracting in water 3 times, each 1 hour, merge extractive liquid, suitably concentrated, and adds the ethanol of 2 times of amounts, leaves standstill 24 hours precipitations, gets supernatant concentration and becomes extractum, and relative density is 1.3~1.4, and paste-forming rate is 10%, and qinghuo reagent adds water and makes oral liquid.

Claims (5)

1. the application of pharmaceutical composition in preparation treatment chronic insufficient cerebral blood supply medicine, wherein the weight proportion of each flavour of a drug of said composition is as follows:
9~11 parts of Radix Ginsengs, the Radix Astragali 39~41,14~16 parts of Radix Angelicae Sinensis, 9~11 parts in Cornu Cervi Pantotrichum, 79~81 parts of Flos Chrysanthemis, 79~81 parts of Herba Menthaes, 79~81 parts of Radix Bupleuri, 79~81 parts of Semen Cassiaes, Herba Schizonepetae 39~41,79~81 parts of Radix Salviae Miltiorrhizaes, 99~101 parts of Radix Polygalaes, 24~26 parts of Fructus Schisandrae Chinensis, 39~41 parts of Semen Ziziphi Spinosaes, 39~41 parts of Plumula Nelumbiniss, 59~61 parts of Radix Ophiopogonis, 59~61 parts of Bulbus Liliies, 19~21 parts of Caulis Bambusae In Taenia, 79~81 parts of Radix Scutellariaes, 79~81 parts of Radix Platycodoniss, 19~21 parts of Pericarpium Citri Reticulataes, 39~41 parts in Poria, 19~21 parts in Radix Glycyrrhizae, 2~3 parts of Rhizoma Zingiberiss, 79~81 parts of Radix Et Rhizoma Rhei, 39~41 parts of Semen Platycladi, 79~81 parts of Rhizoma Acori Graminei, 59~61 parts in Semen Persicae, 19~21 parts of Radix Achyranthis Bidentataes, 14~16 parts of Fructus Viticises, 79~81 parts of Rhizoma Et Radix Notopterygiis, 79~81 parts of Ramulus Uncariae Cum Uncis, 39~41 parts of Radix Puerariaes, 39~41 parts of the Radixs Angelicae Dahuricae, 59~61 parts on Flos Carthami, 59~61 parts of Rhizoma Chuanxiongs, 19~21 parts of Semen Nelumbinis, 9~11 parts of Caulis Akebiaes, 39~41 parts in Gypsum Fibrosum, 19~21 parts of the Rhizoma Pinelliaes, 19~21 parts of Fructus Aurantiis, 1~3 part of Borneolum Syntheticum, 39~41 parts of Cortex Phellodendris, 19~21 parts of the Rhizoma Anemarrhenaes, 59~61 parts of Radix Paeoniae Rubra, 79~81 parts of Fructus Crataegis, 79~81 parts of Rhizoma Ligusticis, 19~21 parts of Radix Saposhnikoviaes, 19~21 parts of Radix Rehmanniae.
2. application according to claim 1, wherein the weight proportion of each flavour of a drug is as follows:
10 parts of Radix Ginsengs, 40 parts of the Radixs Astragali, 15 parts of Radix Angelicae Sinensis, 10 parts in Cornu Cervi Pantotrichum, 80 parts of Flos Chrysanthemis, 80 parts of Herba Menthaes, 80 parts of Radix Bupleuri, 80 parts of Semen Cassiaes, Herba Schizonepetae 40,80 parts of Radix Salviae Miltiorrhizaes, 100 parts of Radix Polygalaes, 25 parts of Fructus Schisandrae Chinensis, 40 parts of Semen Ziziphi Spinosaes, 40 parts of Plumula Nelumbiniss, 60 parts of Radix Ophiopogonis, 60 parts of Bulbus Liliies, 20 parts of Caulis Bambusae In Taenia, 80 parts of Radix Scutellariaes, 80 parts of Radix Platycodoniss, 20 parts of Pericarpium Citri Reticulataes, 40 parts in Poria, 20 parts in Radix Glycyrrhizae, 2.5 parts of Rhizoma Zingiberiss, 80 parts of Radix Et Rhizoma Rhei, 40 parts of Semen Platycladi, 80 parts of Rhizoma Acori Graminei, 60 parts in Semen Persicae, 20 parts of Radix Achyranthis Bidentataes, 15 parts of Fructus Viticises, 80 parts of Rhizoma Et Radix Notopterygiis, 80 parts of Ramulus Uncariae Cum Uncis, 40 parts of Radix Puerariaes, 40 parts of the Radixs Angelicae Dahuricae, 60 parts on Flos Carthami, 60 parts of Rhizoma Chuanxiongs, 20 parts of Semen Nelumbinis, 10 parts of Caulis Akebiaes, 40 parts in Gypsum Fibrosum, 20 parts of the Rhizoma Pinelliaes, 20 parts of Fructus Aurantiis, 2.5 parts of Borneolum Syntheticums, 40 parts of Cortex Phellodendris, 20 parts of the Rhizoma Anemarrhenaes, 60 parts of Radix Paeoniae Rubra, 80 parts of Fructus Crataegis, 80 parts of Rhizoma Ligusticis, 20 parts of Radix Saposhnikoviaes, 20 parts of Radix Rehmanniae.
3. the application of pharmaceutical composition in the hypomnesis medicine that preparation treatment chronic insufficient cerebral blood supply causes, wherein the weight proportion of each flavour of a drug of compositions is as follows:
9~11 parts of Radix Ginsengs, the Radix Astragali 39~41,14~16 parts of Radix Angelicae Sinensis, 9~11 parts in Cornu Cervi Pantotrichum, 79~81 parts of Flos Chrysanthemis, 79~81 parts of Herba Menthaes, 79~81 parts of Radix Bupleuri, 79~81 parts of Semen Cassiaes, Herba Schizonepetae 39~41,79~81 parts of Radix Salviae Miltiorrhizaes, 99~101 parts of Radix Polygalaes, 24~26 parts of Fructus Schisandrae Chinensis, 39~41 parts of Semen Ziziphi Spinosaes, 39~41 parts of Plumula Nelumbiniss, 59~61 parts of Radix Ophiopogonis, 59~61 parts of Bulbus Liliies, 19~21 parts of Caulis Bambusae In Taenia, 79~81 parts of Radix Scutellariaes, 79~81 parts of Radix Platycodoniss, 19~21 parts of Pericarpium Citri Reticulataes, 39~41 parts in Poria, 19~21 parts in Radix Glycyrrhizae, 2~3 parts of Rhizoma Zingiberiss, 79~81 parts of Radix Et Rhizoma Rhei, 39~41 parts of Semen Platycladi, 79~81 parts of Rhizoma Acori Graminei, 59~61 parts in Semen Persicae, 19~21 parts of Radix Achyranthis Bidentataes, 14~16 parts of Fructus Viticises, 79~81 parts of Rhizoma Et Radix Notopterygiis, 79~81 parts of Ramulus Uncariae Cum Uncis, 39~41 parts of Radix Puerariaes, 39~41 parts of the Radixs Angelicae Dahuricae, 59~61 parts on Flos Carthami, 59~61 parts of Rhizoma Chuanxiongs, 19~21 parts of Semen Nelumbinis, 9~11 parts of Caulis Akebiaes, 39~41 parts in Gypsum Fibrosum, 19~21 parts of the Rhizoma Pinelliaes, 19~21 parts of Fructus Aurantiis, 1~3 part of Borneolum Syntheticum, 39~41 parts of Cortex Phellodendris, 19~21 parts of the Rhizoma Anemarrhenaes, 59~61 parts of Radix Paeoniae Rubra, 79~81 parts of Fructus Crataegis, 79~81 parts of Rhizoma Ligusticis, 19~21 parts of Radix Saposhnikoviaes, 19~21 parts of Radix Rehmanniae
4. the application of pharmaceutical composition in the vertigo medicament that preparation treatment chronic insufficient cerebral blood supply causes, wherein the weight proportion of each flavour of a drug of compositions is as follows:
9~11 parts of Radix Ginsengs, the Radix Astragali 39~41,14~16 parts of Radix Angelicae Sinensis, 9~11 parts in Cornu Cervi Pantotrichum, 79~81 parts of Flos Chrysanthemis, 79~81 parts of Herba Menthaes, 79~81 parts of Radix Bupleuri, 79~81 parts of Semen Cassiaes, Herba Schizonepetae 39~41,79~81 parts of Radix Salviae Miltiorrhizaes, 99~101 parts of Radix Polygalaes, 24~26 parts of Fructus Schisandrae Chinensis, 39~41 parts of Semen Ziziphi Spinosaes, 39~41 parts of Plumula Nelumbiniss, 59~61 parts of Radix Ophiopogonis, 59~61 parts of Bulbus Liliies, 19~21 parts of Caulis Bambusae In Taenia, 79~81 parts of Radix Scutellariaes, 79~81 parts of Radix Platycodoniss, 19~21 parts of Pericarpium Citri Reticulataes, 39~41 parts in Poria, 19~21 parts in Radix Glycyrrhizae, 2~3 parts of Rhizoma Zingiberiss, 79~81 parts of Radix Et Rhizoma Rhei, 39~41 parts of Semen Platycladi, 79~81 parts of Rhizoma Acori Graminei, 59~61 parts in Semen Persicae, 19~21 parts of Radix Achyranthis Bidentataes, 14~16 parts of Fructus Viticises, 79~81 parts of Rhizoma Et Radix Notopterygiis, 79~81 parts of Ramulus Uncariae Cum Uncis, 39~41 parts of Radix Puerariaes, 39~41 parts of the Radixs Angelicae Dahuricae, 59~61 parts on Flos Carthami, 59~61 parts of Rhizoma Chuanxiongs, 19~21 parts of Semen Nelumbinis, 9~11 parts of Caulis Akebiaes, 39~41 parts in Gypsum Fibrosum, 19~21 parts of the Rhizoma Pinelliaes, 19~21 parts of Fructus Aurantiis, 1~3 part of Borneolum Syntheticum, 39~41 parts of Cortex Phellodendris, 19~21 parts of the Rhizoma Anemarrhenaes, 59~61 parts of Radix Paeoniae Rubra, 79~81 parts of Fructus Crataegis, 79~81 parts of Rhizoma Ligusticis, 19~21 parts of Radix Saposhnikoviaes, 19~21 parts of Radix Rehmanniae
5. the application of pharmaceutical composition in the encephalopathy medicine that preparation treatment chronic insufficient cerebral blood supply causes, wherein the weight proportion of each flavour of a drug of compositions is as follows:
9~11 parts of Radix Ginsengs, the Radix Astragali 39~41,14~16 parts of Radix Angelicae Sinensis, 9~11 parts in Cornu Cervi Pantotrichum, 79~81 parts of Flos Chrysanthemis, 79~81 parts of Herba Menthaes, 79~81 parts of Radix Bupleuri, 79~81 parts of Semen Cassiaes, Herba Schizonepetae 39~41,79~81 parts of Radix Salviae Miltiorrhizaes, 99~101 parts of Radix Polygalaes, 24~26 parts of Fructus Schisandrae Chinensis, 39~41 parts of Semen Ziziphi Spinosaes, 39~41 parts of Plumula Nelumbiniss, 59~61 parts of Radix Ophiopogonis, 59~61 parts of Bulbus Liliies, 19~21 parts of Caulis Bambusae In Taenia, 79~81 parts of Radix Scutellariaes, 79~81 parts of Radix Platycodoniss, 19~21 parts of Pericarpium Citri Reticulataes, 39~41 parts in Poria, 19~21 parts in Radix Glycyrrhizae, 2~3 parts of Rhizoma Zingiberiss, 79~81 parts of Radix Et Rhizoma Rhei, 39~41 parts of Semen Platycladi, 79~81 parts of Rhizoma Acori Graminei, 59~61 parts in Semen Persicae, 19~21 parts of Radix Achyranthis Bidentataes, 14~16 parts of Fructus Viticises, 79~81 parts of Rhizoma Et Radix Notopterygiis, 79~81 parts of Ramulus Uncariae Cum Uncis, 39~41 parts of Radix Puerariaes, 39~41 parts of the Radixs Angelicae Dahuricae, 59~61 parts on Flos Carthami, 59~61 parts of Rhizoma Chuanxiongs, 19~21 parts of Semen Nelumbinis, 9~11 parts of Caulis Akebiaes, 39~41 parts in Gypsum Fibrosum, 19~21 parts of the Rhizoma Pinelliaes, 19~21 parts of Fructus Aurantiis, 1~3 part of Borneolum Syntheticum, 39~41 parts of Cortex Phellodendris, 19~21 parts of the Rhizoma Anemarrhenaes, 59~61 parts of Radix Paeoniae Rubra, 79~81 parts of Fructus Crataegis, 79~81 parts of Rhizoma Ligusticis, 19~21 parts of Radix Saposhnikoviaes, 19~21 parts of Radix Rehmanniae.
CNA200510013684XA 2005-06-03 2005-06-03 Application of medication composition of containing giant gen-seng in preparing medicine for treating insufficiency of blood supply for brain Pending CN1872329A (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
CNA200510013684XA CN1872329A (en) 2005-06-03 2005-06-03 Application of medication composition of containing giant gen-seng in preparing medicine for treating insufficiency of blood supply for brain

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
CNA200510013684XA CN1872329A (en) 2005-06-03 2005-06-03 Application of medication composition of containing giant gen-seng in preparing medicine for treating insufficiency of blood supply for brain

Publications (1)

Publication Number Publication Date
CN1872329A true CN1872329A (en) 2006-12-06

Family

ID=37483037

Family Applications (1)

Application Number Title Priority Date Filing Date
CNA200510013684XA Pending CN1872329A (en) 2005-06-03 2005-06-03 Application of medication composition of containing giant gen-seng in preparing medicine for treating insufficiency of blood supply for brain

Country Status (1)

Country Link
CN (1) CN1872329A (en)

Cited By (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101766754A (en) * 2010-04-20 2010-07-07 泰一和浦(北京)中医药研究院有限公司 Chinese medicine composite for treating coma and preparation method thereof
CN101698069B (en) * 2009-10-28 2011-01-26 房永红 Traditional Chinese medicine preparation for treating cervical vertigo
CN102133347A (en) * 2011-03-25 2011-07-27 路正平 Drug for treating neurogenic headache
CN101204478B (en) * 2007-12-13 2012-05-30 孙瑞龙 Nose-scenting medicine for chronic nasosinusitis
CN102716459A (en) * 2012-05-08 2012-10-10 四川中方制药有限公司 Chinese medicinal composition for treating senile mild cognitive impairment and preparation method thereof
CN103202964A (en) * 2013-04-23 2013-07-17 山东上水农业发展股份有限公司 Brain-improving and mind-calming medicinal liquor
CN103721028A (en) * 2014-01-23 2014-04-16 李晓霞 Medicament for treating angina pectoris and preparation method thereof
CN104208326A (en) * 2014-09-03 2014-12-17 廖玉兰 Traditional Chinese medicine decoction for treating dizziness caused by insufficient blood supply and preparation method thereof
CN105833184A (en) * 2016-05-09 2016-08-10 三峡大学 Traditional Chinese medicine composition, fermented medicine liquor prepared from traditional Chinese medicine composition, preparation method and application

Cited By (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101204478B (en) * 2007-12-13 2012-05-30 孙瑞龙 Nose-scenting medicine for chronic nasosinusitis
CN101698069B (en) * 2009-10-28 2011-01-26 房永红 Traditional Chinese medicine preparation for treating cervical vertigo
CN101766754A (en) * 2010-04-20 2010-07-07 泰一和浦(北京)中医药研究院有限公司 Chinese medicine composite for treating coma and preparation method thereof
CN102133347A (en) * 2011-03-25 2011-07-27 路正平 Drug for treating neurogenic headache
CN102133347B (en) * 2011-03-25 2012-07-04 路正平 Drug for treating neurogenic headache
CN102716459B (en) * 2012-05-08 2014-06-18 四川中方制药有限公司 Chinese medicinal composition for treating senile mild cognitive impairment and preparation method thereof
CN102716459A (en) * 2012-05-08 2012-10-10 四川中方制药有限公司 Chinese medicinal composition for treating senile mild cognitive impairment and preparation method thereof
CN103202964A (en) * 2013-04-23 2013-07-17 山东上水农业发展股份有限公司 Brain-improving and mind-calming medicinal liquor
CN103721028A (en) * 2014-01-23 2014-04-16 李晓霞 Medicament for treating angina pectoris and preparation method thereof
CN103721028B (en) * 2014-01-23 2016-01-06 李晓霞 One treats anginal medicine and preparation method
CN104208326A (en) * 2014-09-03 2014-12-17 廖玉兰 Traditional Chinese medicine decoction for treating dizziness caused by insufficient blood supply and preparation method thereof
CN105833184A (en) * 2016-05-09 2016-08-10 三峡大学 Traditional Chinese medicine composition, fermented medicine liquor prepared from traditional Chinese medicine composition, preparation method and application
CN105833184B (en) * 2016-05-09 2019-07-26 三峡大学 A kind of Chinese medicine composition, fermentation medical fluid of its preparation and preparation method and application

Similar Documents

Publication Publication Date Title
CN1872329A (en) Application of medication composition of containing giant gen-seng in preparing medicine for treating insufficiency of blood supply for brain
CN100592918C (en) Application of medication composition containing magnolia vine fruit in preparing medicine for treating insufficiency of blood supply for brain
CN1872287A (en) Application of medication composition of containing gastrodia tuber in preparing medicine for treating insufficiency of blood supply for brain
CN1872214B (en) Application of medication composition of containing notoperygium root in preparing medication for treating chronic insufficiency of supplying blood for brain
CN1872187B (en) Application of medication composition of containing astragalus root in preparing medication for treating chronic insufficiency of supplying blood for brain
CN1872081B (en) Application of kudzuvine root flavone in preparing medicine for treating chronic insufficiency of blood supply for brain
CN1872291A (en) Application of medication composition of containing uncaria in preparing medicine for treating insufficiency of blood supply for brain
CN100411652C (en) Use of medicinal composition in preparing medicine for treating chronic brain blood supply deficiency
CN1872276B (en) Application of medication composition of containing extractive of astragalus root in preparing medicine for treating insufficiency of blood supply for brain
CN1872288A (en) Application of medication composition of containing eucommia in preparing medicine for treating insufficiency of blood supply for brain
CN1872213B (en) Application of medication composition of containing peach kernel in preparing medication for treating chronic insufficiency of supplying blood for brain
CN100548362C (en) A kind of Rhizoma Typhonii pharmaceutical composition that contains is preparing the application for the treatment of in the chronic insufficient cerebral blood supply medicine
CN1872297B (en) Application of medication composition of Guangdong date in preparing medicine for treating chronic insufficiency of blood supply for brain
CN100455316C (en) Use of medicinal composition containing ligusticum wallichii for treating chronic brain blood supply deficiency
CN100563699C (en) A kind of application of pharmaceutical composition in the medicine of preparation treatment chronic insufficient cerebral blood supply that contains Rhizoma Ligustici
CN1814163A (en) Chinese medicine for treating cardiovascular and cerebrovascular trrombus and preparing method
CN100563692C (en) A kind of application of pharmaceutical composition in the medicine of preparation treatment chronic insufficient cerebral blood supply that contains Magnetitum
CN1872170B (en) Application of medication composition of containing corydalis tuber in preparing medication for treating chronic insufficiency of supplying blood for brain
CN1872154B (en) Application of medication composition of containing Yunnan red sage root in preparing medication for treating chronic insufficiency of supplying blood for brain
CN100450539C (en) Use of medicinal composition containing pilose antler for treating chronic brain blood supply deficiency
CN1872319B (en) Application of medication composition of containing polygala root in preparing medicine for treating insufficiency of blood supply for brain
CN1872290A (en) Application of gastrodia tuber in preparing medicine for treating insufficiency of blood supply for brain
CN1714851A (en) Use of medicinal composition containing gastrodia elata for treating chronic brain blood supply deficiency
CN1872145A (en) Application of medication composition of containing caltrop in preparing medication for treating chronic insufficiency of supplying blood for brain
CN1872286B (en) Application of medication composition of containing notoginseng in preparing medicine for treating insufficiency of blood supply for brain

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
C12 Rejection of a patent application after its publication
RJ01 Rejection of invention patent application after publication

Open date: 20061206